GMDA News and Press, Gamida Cell Ltd. From 06/01/22

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced the activation of the initial clinical sites to screen and enroll patients in the company...

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that company management will present at the upcoming H.C. Wainwright Global Life Sciences Conferen...

Image source: The Motley Fool. Gamida Cell Ltd. (NASDAQ: GMDA) Q1 2022 Earnings Call May 10, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Gamida Cell Ltd. (GMDA) Q1 2022 Earnings Call Transcript

Gamida Cell Ltd. (GMDA) Q1 2022 Results Conference Call May 10, 2022 08:00 AM ET Company Participants Heather DiVecchia - Chief of Staff Michele Korfin - Chief Operating Officer and Chief Commercial Officer Ronit Simantov - Chief Medical Officer and Chief Scientific Officer Shai Lankry - Chie...

Gamida Cell press release (NASDAQ:GMDA): Q1 GAAP EPS of -$0.34 in-line. The company expects that its current cash and cash equivalents of $70M will support the company’s ongoing operating activities into mid 2023. This cash runaway guidance is based on the company’s current oper...

- On track for full BLA submission of omidubicel in the second quarter of 2022 - - Planning to open sites for enrollment in second quarter of 2022 for Phase 1/2 study of GDA-201 in patients with follicular and diffuse large B-cell lymphomas - - Presented new precli...

Poster selected for inclusion in conference’s Elevator Pitch Session: GDA-301 produces enhanced potency and persistence with combined genetic manipulation of CISH gene editing and the engineered expression of membrane-bound IL-15 for targeting hematologic malignancies and sol...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, May 10, 2022, at 8:00 a.m. ET to review its first quarter 20...

Shares of Gamida Cell (NASDAQ:GMDA) have fallen 8% to $2.48 in morning trade on Wednesday, a day after gaining as much as 16%. GMDA on April 26 said the U.S. Food and Drug Administration (FDA) had cleared its new drug application and lifted the clinical hold for a cryopreserved formulation of...

Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate with breakthrough and orphan drug designations being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant Update...